Clicky

Beam Therapeutics Inc.(BEAM)

Description: Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. It is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. The company was founded in 2017 and is based in Cambridge, Massachusetts.


Keywords: Biotechnology Cancer Gene Therapy Acute Myeloid Leukemia Leukemia Central Nervous System Disorders Serious Diseases Nervous System Disorders Acute Lymphoblastic Leukemia Antitrypsin Deficiency Acute Leukemia Sickle Cell Disease Thalassemia Beta Thalassemia Glycogen Storage Disorder

Home Page: www.beamtx.com

BEAM Technical Analysis

238 Main Street
Cambridge, MA 02142
United States
Phone: 857 327 8775


Officers

Name Title
Mr. John M. Evans M.B.A. CEO & Director
Dr. Giuseppe Ciaramella Ph.D. Pres & Chief Scientific Officer
Ms. Terry-Ann Burrell M.B.A. CFO & Treasurer
Dr. Feng Zhang Ph.D. Co-Founder
Dr. David R. Liu Ph.D. Co-Founder
Dr. J. Keith Joung M.D., Ph.D. Co-Founder
Dr. Nicole Gaudelli Ph.D. Co-Founder
Dr. Alexis Komor Ph.D. Co-Founder
Ms. Suzanne Fleming Chief Accounting Officer
Mr. Brian Riley Sr. VP of Technical Operations

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 4.4265
Price-to-Sales TTM: 32.425
IPO Date: 2020-02-06
Fiscal Year End: December
Full Time Employees: 507
Back to stocks